Christoph Schumacher

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

John R. Teerlink, Gad Cotter, Beth A. Davison et al. · The Lancet · 2012 · 896 citations

Heart Failure, Cardiac Anaesthesia, Cardiogenic Shock +10

Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program

Marco Metra, Gad Cotter, Beth A. Davison et al. · Journal of the American College of Cardiology · 2012 · 423 citations · Full text

Heart Failure, Stress, Medicine +10

Structure-activity relationships of interleukin-8 determined using chemically synthesized analogs. Critical role of NH2-terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities.

Ian Clark‐Lewis, Christoph Schumacher, Marco Baggiolini et al. · Journal of Biological Chemistry · 1991 · 423 citations · Full text

Immunology, Immune Regulation, Nh2-terminal Residues +18

Neutrophil-activating peptide 2 and gro/melanoma growth-stimulatory activity interact with neutrophil-activating peptide 1/interleukin 8 receptors on human neutrophils

Bernhard Moser, Christoph Schumacher, V von Tscharner et al. · Journal of Biological Chemistry · 1991 · 222 citations · Full text

Inflammation, Cytokine, Ligand Cross-linking +15

High- and low-affinity binding of GRO alpha and neutrophil-activating peptide 2 to interleukin 8 receptors on human neutrophils.

Christoph Schumacher, Ian Clark‐Lewis, Marco Baggiolini et al. · Proceedings of the National Academy of Sciences · 1992 · 197 citations · Full text

Inflammation, Gro Alpha, Cytokine +14